Pfizer Inc. (PFE) said that Tafamidis received Breakthrough Therapy designation from the U.S. Food and Drug Administration or FDA for the treatment of patients with transthyretin cardiomyopathy, a rare, fatal, and underdiagnosed condition associated with progressive heart failure.
from RTT - Biotech https://ift.tt/2khv7aM
via IFTTT
No comments:
Post a Comment